See all locations for this study
Phase 3Starting soon

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Sponsored by Novo Nordisk A/S

About this study

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Enrolling at this location

Gilbert Center For Family Medicine

Gilbert, Arizona

I'm interested

This study also enrolls at 39 other locations. See all.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.